RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
Effective June 15, 2017, Relmada Therapeutics, Inc. (the Company)
appointed Charles J. Casamento as Chairman of the Board of the
Company. Mr. Casamento has been our director since July 2015 and
serves as Chairman of the Audit Committee, and is also a member
of the compensation and the corporate governance committees. Mr.
Casamento will receive additional compensation of $50,000 per for
his role as Chairman of the Board.
On June 12, 2017, Relmada Therapeutics, Inc. (the Company) and
Maged Shenouda, a director of the Company, entered into a
Consulting Agreement (the Agreement). to the terms of the
Agreement, Mr. Shenouda will assist the Company with matters that
may be requested by the Company. Mr. Shenouda will be paid a
consulting fee of $10,000 per month. The term of the Agreement is
for one year. A copy of the Agreement will be included as an
exhibit to the Companys Form 10-K for the year ending June 30,
2017.
About RELMADA THERAPEUTICS, INC. (OTCMKTS:RLMD)
Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to treat chronic pain. Its product candidates include d-Methadone (dextromethadone, REL-1017), LevoCap ER (REL-1015), BuTab (REL-1028) and MepiGel (REL-1021). Its d-Methadone is an N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain. Its REL-1015 is an extended release, abuse deterrent formulation of the opioid analgesic levorphanol, which is pharmacologically differentiated from morphine, oxycodone and other opioids for the management of pain severe enough to require daily, around-the-clock and long-term opioid treatment. REL-1028 represents formulations of oral, modified release buprenorphine being developed for both chronic pain and opioid dependence indications. REL-1021 is a topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies.
